[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
October 1965

Intravenous Metyrapone Test in Chromophobe Adenoma

Author Affiliations


From the University of Texas M. D. Anderson Hospital and Tumor Institute. Associate Internist Department of Medicine (Dr. Cole). Clinical fellow, American Cancer Society, 1963-1964, and presently at Catholic Medical College, St. Mary's Hospital, Seoul, Korea (Dr. Min).

Arch Intern Med. 1965;116(4):581-585. doi:10.1001/archinte.1965.03870040095019

Introduction  BECAUSE of the recent innovation of the metyrapone test as a measure of endogenous ACTH reserve,1,2 methodological variations on this technique have not been clarified. The dosage, route, and time of day the drug is administered are as important to the final result of the test as is the selection of the appropriate steroid analytical procedures.3 The paucity of reports concerning use of the intravenous route of administration and the current controversy over the results even in normal individuals 4 prompt us to report our experience.This study documents the findings in control subjects and in patients with chromophobe adenoma of the pituitary gland. Increments in the total urinary Porter-Silber chromogens which occurred after the administration of intravenous metyrapone were employed as an indirect measure of pituitary adrenocorticotrophic hormone (ACTH) reserve.

Materials and Methods  Thirteen control subjects and eighteen patients with chromophobe adenoma seen at The University